Since the beginning of 2024, the rectification of the pharmaceutical field has not been reduced. In many places, market supervision and administration bureaus, centers for disease control and prevention, medical institutions, and even community health service centers have made public corruption supervision**, solicited clues on bribery in the pharmaceutical field, and accepted rectification reports.
On February 7, the Community Health Service Center of Hangyu Road, Yuyang District, Yulin City, Shaanxi Province, Taiyuan People's Hospital of Shanxi Province, and the Xianyang City Center for Disease Control and Prevention of Shaanxi Province announced the relevant **, and the reporting clues focused on the corruption of the administrative departments in the field of medicine to seek rent, the corruption of the "key minority" and key positions in medical and health institutions, focusing on the "gold sales" of drugs, devices, and consumables, and other corruption issues that are prone to occur frequently, and corruption issues involving the use of medical insurance.
Deng Yong, a professor of health law at Beijing University of Chinese Medicine, told the People's Health Client reporter that in the process of this round of pharmaceutical rectification, various relevant institutions have been seen, which is a positive signal for the promotion of anti-corruption work. "The remediation of the pharmaceutical field is a very complex and arduous task, which requires the joint efforts of the company, regulatory agencies, medical institutions, pharmaceutical companies and the public. The regulatory authorities should strengthen the supervision of medical institutions and medical practitioners, establish a regulatory network for the medical industry, strengthen the inspection and evaluation of medical institutions, and ensure that medical institutions and medical practitioners comply with relevant laws and regulations. At the same time, strengthen the supervision of medical devices and drugs to ensure that the quality is qualified and reasonable. ”
In addition to collecting leads, the supervision of irregularities on the part of pharmaceutical companies has also been tightened. Since the beginning of this year, Anhui, Hunan, Lijiang, Yunnan, Shenzhen, Guangdong and other places have publicly issued "warning letters" to drug marketing authorization holders, medical device registration and filing persons and other enterprises to remind them to strictly prevent commercial bribery in the pharmaceutical field.
For example, on January 15, the official website of the Anhui Provincial Food and Drug Administration notified that the seventh branch of the bureau issued the "Reminder and Warning Letter to Regulate the Code of Conduct for Medical Representatives" to all pharmaceutical and medical device production and operation enterprises in the jurisdiction, reiterating and clarifying the seven prohibited behaviors of medical representatives.
On January 11, the Shantou Municipal Administration for Market Regulation in Guangdong Province issued the "Reminder and Warning Letter for Fair Competition and Compliance Operation of Medical Device Enterprises", emphasizing that the relevant personnel of the enterprise shall give property or other improper benefits to the person in charge of the medical institution, medical device procurement personnel, physicians and other relevant personnel who use its medical devices.
In Deng Yong's view, both the external regulatory environment and the internal industry ecology have put forward new requirements for the compliance construction of pharmaceutical companies. "Lack of awareness, imperfect systems, and weak supervision require the establishment and improvement of corporate compliance systems. Deng Yong said, including compliance management system, risk prevention system, internal control system, regulatory compliance system, etc., to ensure the compliance operation of enterprises. In addition, it is necessary to strengthen the compliance supervision of enterprises and hospitals, establish and improve the supervision mechanism, and ensure the compliance operation of enterprises.